Page 24 - Amendment Agreement News Today : Breaking News, Live Updates & Top Stories | Vimarsana

IAG amends Air Europa agreement International Airlines Group (IAG) and Globalia have announced that they have amended the original agreement announced on 4 November 2019 under which IAG's subsidiary, Iberia, has agreed to acquire the entire issued share capital of Air Europa. Under the terms of the Amendment Agreement, the parties have agreed that the amount to be paid by Iberia for Air Europa will be reduced from an equity value of €1 billion to €500 million with payment deferred until the sixth anniversary of the Acquisition’s completion. The revised terms in the Amendment Agree...

Carnival PLC - Carnival Amendment to Credit Agreement PR Newswire Carnival Corporation and Carnival plc Announce Amendment of Multicurrency Resolving Credit Agreement MIAMI (January 6, 2021) - Carnival Corporation & plc (NYSE/LSE: CCL; NYSE: CUK) announce that its joint current report on Form 8-K was filed with the U.S. Securities and Exchange Commission on January 6, 2021. As described in the joint current report on Form 8-K, on December 31, 2020, Carnival Corporation, Carnival plc and certain of their subsidiaries entered into an Amendment Agreement (the "Amendment Agreement") to the multi...

About Acacia Pharma Acacia Pharma is a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures, or cancer chemotherapy. The Company has identified important and commercially attractive unmet needs in these areas that its product portfolio aims to address. Acacia Pharma's first product, BARHEMSYS ® (amisulpride injection) is available in the US for the management of postoperative nausea & vomiting (PONV). BYFAVO™ (remimazolam) for inje...

Acacia Pharma Announces Amendment of its Investment Agreement with Cosmo Pharmaceuticals for BYFAVO™ €5 million commercialization milestone to be paid by Acacia Pharma to Cosmo in New Ordinary Shares BYFAVO expected to be launched in the United States within the coming weeks This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. Cambridge, UK and Indianapolis, US – 15 December 2020: Acacia Pharma Group plc (“Acacia Pharma”, the “Group” or the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical comp...

Correction: Acacia Pharma Announces Amendment of its Investment Agreement with Cosmo Pharmaceuticals for BYFAVO™ Acacia Pharma Group plc Cambridge, UNITED KINGDOM Issue price of new ordinary shares to Cosmo in para 8 should be in EUROS rather than GBP and details of Cosmo’s holding post the issue has been added as a final para Correction - Acacia Pharma Announces Amendment of its Investment Agreement with Cosmo Pharmaceuticals for BYFAVO™ €5 million commercialization milestone to be paid by Acacia Pharma to Cosmo in New Ordinary Shares BYFAVO expected to be...